TABLE 25Discontinuations due to AEs

StudyLength of follow-up (months)Dose (mg)Discontinuation
Kantarjian et al. (2007),6 (2009)715a400 b.i.d.9/49 = 18.4 %
26b400 b.i.d.10/49 = 20.4 %
cKoh et al. (2010)1012600 or 8000/71 = 0 %d
Rajappa et al. (2010)8188003/90 = 3.3 %

AP, accelerated phase; BC, blast crisis; CP, chronic phase; HDI, high-dose imatinib.

a

At median follow-up of 15 months (range 1 to 21 months), 80% of HDI participants had crossed over to alternative treatment, median treatment duration 3.1 months (range 0.2 to 15.6 months).

b

At study median follow-up of 26 months (range 6.9 to 32.7 months), 80% of HDI participants had crossed over to alternative treatment, median treatment duration 3 months (range 0.16 to 26.3 months).

c

Study included CP (n = 64), AC (n = 3) and BC (n = 4)

d

Number who stopped imatinib owing to ‘intolerable toxicity’.

From: 3, Clinical effectiveness

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.